A Phosphodiesterase Type-5 (PDE-5) Inhibitor, Sildenafil, Ameliorates the NEC Induced Inflammation

Mehmet Akif Ovalı1, Özlem Öztopuz2, İhsan Karaboğa3

  • 1Faculty of Medicine, Department of Physiology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey. maovali@comu.edu.tr.

The Protein Journal
|March 8, 2025
PubMed

Insights

Sildenafil treatment reduced inflammation and lung tissue damage in a neonatal rat model of necrotizing enterocolitis (NEC). This finding highlights sildenafil's therapeutic potential for gut-lung axis disorders.

Area of Science:

  • Neonatology
  • Pulmonology
  • Gastroenterology

Background:

  • The gut-lung axis describes the relationship between the gut microbiota and lung diseases, impacting homeostasis and disease.
  • Necrotizing enterocolitis (NEC) is a critical gastrointestinal complication in newborns, often accompanied by pulmonary issues causing significant morbidity.

Purpose of the Study:

  • To investigate the therapeutic effects of sildenafil on lung tissue inflammation and histopathological alterations in a neonatal rat model of experimental necrotizing enterocolitis.

Main Methods:

  • Neonatal Wistar Albino rats were divided into control, NEC, and varying sildenafil dose groups.
  • NEC was induced via hypoxia/asphyxia and cold stress.
  • Lung tissues were analyzed for histopathological changes (H&E, Masson trichrome staining) and mRNA expression of TNF-α, IL-6, and HSPa5.

Main Results:

  • NEC group showed increased mRNA levels of TNF-α, IL-6, and HSPa5 compared to controls.
  • Sildenafil treatment significantly reduced these inflammatory markers and associated lung tissue damage (edema, hemorrhage).
  • Histopathological findings showed reduced alveolar and interstitial edema and hemorrhage in sildenafil-treated groups.

Conclusions:

  • Sildenafil demonstrates a therapeutic effect on NEC-induced lung inflammation at both molecular and tissue levels.
  • The findings suggest sildenafil's potential as a treatment for lung complications associated with NEC.
  • This study underscores the therapeutic potential of targeting the gut-lung axis in neonatal critical illnesses.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
124
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
4.9K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
455
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
486
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
360